COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No.
作者信息
Jimenez David, Rali Parth, Doerschug Kevin
机构信息
Respiratory Medicine, Ramón y Cajal Hospital (IRYCIS), and CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.
出版信息
Chest. 2022 Jun;161(6):1448-1451. doi: 10.1016/j.chest.2022.01.037. Epub 2022 Mar 15.
Abstract
摘要
相似文献
1
COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No.正方观点：是否应对新冠肺炎急性住院患者使用治疗性肝素？不应该。
Chest. 2022 Jun;161(6):1448-1451. doi: 10.1016/j.chest.2022.01.037. Epub 2022 Mar 15.
2
POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes.观点：是否应对患有新冠肺炎的急性病住院患者使用治疗性肝素？答案是肯定的。
Chest. 2022 Jun;161(6):1446-1448. doi: 10.1016/j.chest.2022.01.036. Epub 2022 Mar 15.
3
Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.治疗剂量肝素对因 COVID-19 住院患者的治疗效果
JAMA. 2023 Aug 1;330(5):471-472. doi: 10.1001/jama.2023.9535.
4
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.住院 COVID-19 患者的凝血病：治疗性抗凝与标准治疗作为对 COVID-19 大流行的快速反应的实用随机对照试验 (RAPID COVID COAG - RAPID 试验)：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
5
Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19-Reply.治疗剂量肝素对因 COVID-19 住院患者的治疗效果——回复
JAMA. 2023 Aug 1;330(5):472-473. doi: 10.1001/jama.2023.9538.
6
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.急性病医学患者中用于预防血栓栓塞并发症的克赛®与未分级肝素的疗效和安全性的开放性标签比较：CERTAIN 研究。
Expert Opin Pharmacother. 2010 Dec;11(18):2953-61. doi: 10.1517/14656566.2010.521498. Epub 2010 Oct 18.
7
Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study.依诺肝素与未分级肝素预防心力衰竭住院患者静脉血栓栓塞事件的比较：随机对照 CERTIFY 研究的亚组分析。
Am Heart J. 2011 Feb;161(2):322-8. doi: 10.1016/j.ahj.2010.10.005.
8
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
9
Prevention of venous thromboembolism in the hospitalized medical patient.住院内科患者静脉血栓栓塞的预防
Cleve Clin J Med. 2008 Apr;75 Suppl 3:S7-16. doi: 10.3949/ccjm.75.suppl_3.s7.
10
Prophylaxis for thromboembolism in hospitalized medical patients.住院内科患者血栓栓塞的预防
N Engl J Med. 2007 Jul 19;357(3):305; author reply 305-6.
引用本文的文献
1
From Emergence to Endemicity: A Comprehensive Review of COVID-19.从出现到地方性流行：对新冠病毒病的全面综述
Cureus. 2023 Oct 31;15(10):e48046. doi: 10.7759/cureus.48046. eCollection 2023 Oct.
2
Role of Therapeutic Anticoagulation in COVID-19: The Current Situation.治疗性抗凝在新型冠状病毒肺炎中的作用：现状
Hematol Rep. 2023 Jun 5;15(2):358-369. doi: 10.3390/hematolrep15020037.
3
Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach.评估治疗组合对 SARS-CoV-2 感染患者结局的影响：大数据方法。
PLoS One. 2023 Mar 9;18(3):e0282587. doi: 10.1371/journal.pone.0282587. eCollection 2023.
4
Incidence of lower limb deep vein thrombosis in patients with COVID-19 pneumonia through different waves of SARS-CoV-2 pandemic: A multicenter prospective study.COVID-19 肺炎患者下肢深静脉血栓形成的发生率在不同波次 SARS-CoV-2 流行期间：一项多中心前瞻性研究。
PLoS One. 2023 Feb 2;18(2):e0280247. doi: 10.1371/journal.pone.0280247. eCollection 2023.
5
Rebuttal From Dr Tritschler et al.特里奇勒博士等人的反驳
Chest. 2022 Jun;161(6):1451-1453. doi: 10.1016/j.chest.2022.01.039. Epub 2022 Mar 15.
本文引用的文献
1
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.治疗性肝素与预防性肝素对中症 COVID-19 住院患者的死亡、机械通气或入住重症监护病房的影响：RAPID 随机临床试验。
BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
2
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
3
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.不同预防性抗凝剂量方案在 COVID-19 危重症和非危重症患者中的安全性和有效性：一项随机对照试验的系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):677-686. doi: 10.1093/ehjcvp/pvab070.
4
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
5
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
6
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.新冠病毒病（COVID-19）合并D-二聚体浓度升高住院患者的治疗性与预防性抗凝治疗（ACTION）：一项开放标签、多中心、随机对照试验
Lancet. 2021 Jun 12;397(10291):2253-2263. doi: 10.1016/S0140-6736(21)01203-4. Epub 2021 Jun 4.
7
Pulmonary Artery Filling Defects in COVID-19 Patients Revealed Using CT Pulmonary Angiography: A Predictable Complication?利用CT肺血管造影术揭示的COVID-19患者肺动脉充盈缺损：一种可预测的并发症？
Biomed Res Int. 2021 Mar 10;2021:8851736. doi: 10.1155/2021/8851736. eCollection 2021.
8
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.COVID-19 重症监护患者中中剂量与标准剂量预防抗凝对血栓事件、体外膜肺氧合治疗或死亡率的影响：INSPIRATION 随机临床试验。
JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.
9
Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study.中至大剂量依诺肝素治疗的重症 COVID-19 患者的肺栓塞：一项回顾性研究。
Monaldi Arch Chest Dis. 2021 Mar 16;91(3). doi: 10.4081/monaldi.2021.1758.
10
Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.COVID-19 住院患者静脉血栓栓塞症和出血的发生率：系统评价和荟萃分析。
Chest. 2021 Mar;159(3):1182-1196. doi: 10.1016/j.chest.2020.11.005. Epub 2020 Nov 17.
Zotero 插件